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ScienceDirectThe gut microbiome — the largest reservoir of microorganisms of
the human body — is emerging as an important player in
neurodevelopment and ageing as well as in brain diseases
including stroke, Alzheimer’s disease and Parkinson’s disease.
The growing knowledge on mediators and triggered pathways has
advancedourunderstandingof the interactionsalongthegut-brain
axis. Gut bacteria produce neuroactive compounds and can
modulate neuronal function, plasticity and behavior. Furthermore,
intestinal microorganisms impact the host’s metabolism and
immunestatuswhichin turnaffectneuronalpathways in theenteric
and central nervous systems. Here, we discuss the recent insights
from human studies and animal models on the bi-directional
communication along the microbiome-gut-brain axis in both acute
and chronic brain diseases.
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Introduction
A relatively small fraction of chronic human diseases can
be explained by genetic factors alone. Exposure to envi-
ronmental factors and the resulting gene-environment
interactions have been postulated to play an important
role in disease initiation and progression [1]. Highlywww.sciencedirect.com diverse, complex communities of microorganisms com-
prising bacteria, archaea, microeukaryotes and viruses
populate the human body whereby the gut represents
the largest reservoir of microbial biomass [2]. Differences
in the relative abundance, the composition and function
of the gut microbiome between healthy individuals and
patients have been described for a range of human
diseases including autoimmune, metabolic and neurode-
generative diseases as well as cancer [3,4]. The impor-
tance of peripheral organs in the development of brain
pathologies has long been considered marginal in the field
of neurobiology. However, gut microbiota homeostasis
and the associated host intestinal health not only impact
the gastrointestinal tract (GIT) environment but also
distant organs, including the brain [5]. The gut micro-
biome’s early colonization is vital for brain function and
behavior considering that its absence results in an
impairment of the blood brain barrier (BBB), alteration
of synapse plasticity and social behavior deficits [6,7].
Germ-free (GF) mice also show an immature microglial
phenotype leading to impaired immune responses [8].
Bi-directional communication between the gut and the
brain implies a key role for the gut microbiome via the
regulation of the host metabolism, immune and vascular
systems [9]. Furthermore, the gut microbiota may also
influence the central nervous system (CNS) via the vagus
nerve (VN) by transmitting gut microbiome signals to the
brain and vice versa in both health and disease [10]. In the
present review, we focus on the role of the microbiome in
a selection of major neurological disorders and discuss
the current state of knowledge about the microbiome’s
impact on disease outcome and the potential mechanisms
involved in these interactions. Specifically, we discuss the
impact of the microbiome in stroke as a paradigm of acute
brain injury as well as its role in two highly prevalent
neurodegenerative disorders, namely Alzheimer’s disease
(AD) and Parkinson’s disease (PD). This review of acute
and chronic neurological disorders highlights common
effects, as well as differences in the microbiome-brain
axis between these diseases (Figure 1).
Gut microbiome alteration in acute and
chronic brain diseases
Experimental and clinical studies indicate that stroke risk
and outcome are substantially impacted by the gut micro-
biota composition [11,12,13]. It has been observed
that significant changes of the microbial compositionCurrent Opinion in Neurobiology 2020, 61:1–9
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Effect of GF on brain pathology.
Major neuronal and inflammatory mechanisms implicated in stroke, AD and PD in comparison to non-diseased condition as demonstrated in
animal models. All of the three diseases lead to gut microbiome dybiosis, neuronal death, behavioral deficits, microglia activation, pro-
inflammatory milieu in the gut, intestinal motility impairment and/or increased gut permeability. In a context of GF condition, microglia showed an
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Gut-brain-axis in neurological diseases Benakis et al. 3are apparent in the gut during the acute phase of stroke
[12,14,15] which has been correlated with the severity of
brain lesions. Singh et al. showed that the bacterial diver-
sity in stool is reduced in mice with a severe stroke,
whereas the microbiome of mice subjected to a mild
stroke was identical to controls. The overall changes were
reflected in a reduction of the Firmicutes with a concom-
itant overgrowth of Bacteroidetes, representing the two
main bacterial phyla in the gut. This shift was associated
with reduced intestinal motility and an increased perme-
ability of the intestinal wall [12]. Shifts in the microbial
populations were also observed in several portions
along the GIT during the acute phase of stroke
[14,15]. However, when analyzing microbiota changes
at lower taxonomic ranks, some discrepancies regarding
specific bacterial changes were observed across these
studies. Houlden et al. found an increase in Peptococca-
ceae (Firmicutes phylum) and a decrease of Prevotella-
ceae (Bacteriodetes); Stanley et al. showed an increased
abundance of Akkermansia muciniphila (Verrucomicrobia)
and Clostridiales species (Firmicutes). Several differ-
ences in the experimental design could account for these
differences, such as location of sampling (cecum versus
small intestine), methods used for the extraction of geno-
mic DNA and for 16S rRNA analysis, the severity of the
stroke model and the baseline differences in the micro-
biota composition based on the provenance of the mice
[16]. In turn, eradication of the microbiome in GF animals
had a negative impact on stroke outcome (Figure 1) in
comparison to control mice and GF mice colonized with a
specific-pathogen-free (SPF) microbiome in early life
(ex-GF mice) [12]. In an attempt to resolve causal
interdependencies, modification of the gut microbiome
was performed using antibiotics before the induction of
stroke. After two weeks of antibiotic treatment, there was
a transient reduction in the bacterial density and an
elimination of Clostridia and Bacteroidetes with a con-
comitant expansion in Proteobacteria. This shift was
associated with an improved stroke outcome as shown
by a significant reduction in the infarct volume and
improvement of sensory and motor functions [11]. To
demonstrate causality, colonization with the microbiome
from the antibiotic-treated mice — ‘neuroprotective
microbiome’ — before the induction of stroke prevented
the development of the infarct. Differences in the abun-
dances of Ruminococcaceae, Verrucomicrobiaceae and
Prevotellaceae can discriminate between the severity
of brain damage - the larger the lesion volume the more
pronounced the changes in the microbiota composition.
Additionally, recent findings have identified that the
microbiome from aged mice is associated with an imbal-
ance of the ratio Firmicutes:Bacteroidetes in comparison
to young mice. Interestingly, fecal matter transplantation(Figure 1 Legend Continued) immature morphology suggesting a defective
had a more severe brain pathology in comparison to SPF mice showed by 
AD and PD, aggregation of Ab and SNCA was reduced, respectively and w
www.sciencedirect.com from young mice into aged mice improved overall stroke
outcome [17].
Clinical studies in stroke patients indicate an increase in
diversity, a slight decrease in members of the phylum
Bacteroidetes [18] and an increase in Lactobacillus ruminis
(from the phylum Firmicutes) [13]. In contrast, analysis of
fecal samples collected from AD patients has revealed a
reduced diversity as well as an increased abundance in
Bacteroidetes that was reproducible in animal models
[19,20]. The composition of the PD microbiome in
patients is characterized by increased abundances
of Akkermansia, Bifidobacteriaceae, Enterobacteriaceae,
Lactobacillaceae, and a dramatic decrease of Prevotella-
ceae which belongs to the phylum Bacteroidetes [21,22].
However, these specific changes have not been recapitu-
lated by all studies in PD [23] although some are already
apparent at prodromal stages of the disease [22].
Discrepancies in the shift of the microbiome between
the different studies, and between patients and rodents,
may be explained by confounding factors. Indeed, the
observable shifts in the gut microbiome in PD might be
linked to the gastrointestinal symptoms, for example,
constipation, which are encountered in most patients
[24]. In stroke patients, some of the identified shifts in
the microbiota composition have been clearly associated
with type-2 diabetes and the severity of the stroke [13],
suggesting more complex interactions between the gut
microbiome in patients with comorbidities and their
impact on brain diseases. A disease-specific microbial
‘fingerprint’ has not yet been identified but might arise
from future studies investigating larger patient cohorts
and performing a more thorough characterization of the
gut microbiome including functional analyses. Further-
more, consensus on molecular techniques, taxonomic
levels, sample types and confounding factors should also
be reached to allow comprehensive comparisons.
In contrast to stroke, in an AD mouse model, the lack or
alteration of the gut microbiome in GF and antibiotic-
treated mice, has been associated with a beneficial effect
on AD pathology as shown by a reduced amyloid- b (Ab)
deposition (Figure 1) –– according to the ‘amyloid
hypothesis’ deposition Ab plaques are the cause of
neuronal degeneration and cognitive decline [25,26].
Normalization of the antibiotics-induced changes using
fecal transplants from control mice was able to at least
partially restore AD pathology, indicating a causative role
for the gut microbiome in some aspects of AD pathophysi-
ology [27]. Interestingly, modification of the microbiome in
AD mice was associated with a reduction in microglial
activation [25,26,28]. Similarly, using a severe mouse
model of PD overexpressing the human a-synuclein response to the brain damage. Indeed, GF mice subjected to stroke
an increase of the lesion volume. However, in a GF mouse model of
as associated with a better outcome.
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4 Neurobiology of disease(SNCA; aggregations of this protein in dopaminergic
neurons are the majormolecularhallmarkof thepathology),
Sampson et al. demonstrated that depletion of the gut
microbiome reduced activation of microglia, motor deficits
and GI defects, as well as SNCA aggregates in the brain,
showing a better SNCA-associated brain pathology in mice
depleted of gut microbiota (Figure 1) [29]. Remarkably,
colonization of these mice with a PD-derived gut micro-
biome from patients further enhanced motor dysfunction
[29]. However, following experimental stroke, microglia
were less activated in the contralateral side of GF mice in
comparison to ex-GF mice. In contrast to AD and PD, the
lack of microglia response in GF mice was associated with
a worsened stroke outcome [30]. This is particularly
interesting, because the findings in AD and PD contrast
with the common understanding that microglia are mainly
involved in the phagocytosis of Ab plaques and SNCA,
respectively. Hence, an impaired activation is assumed to
be associated with increased aggregates and reduced clear-
ance. Together, the unexpected association of reduced
microglial activation and lower pathological hallmarks of
AD and PD with an altered microbial community needs to
be further explored. In fact, the molecular mechanisms
underlying microglia activation in relation to the gut micro-
biome and their effects in the development of acute and
chronic brain disorders require further study. Additional
immunological considerations about the involvement of
alternative gut-immune pathways and gut metabolites in
AD, PD and stroke beyond a putative role of microglia are
further discussed below.
Microbiota-gut-brain axis mediators in acute
and chronic diseases
Immune cells and the gut microbiome
The GIT is continuously exposed to millions of micro-
biome-derived molecules. Through constant contact with
the microbial molecules, epithelial and immune cells in the
gut have evolved a capacity to maintain a homeostatic state
by defending host integrity while promoting tolerogenic
responses to commensal microbes. Under healthy condi-
tions, regulatory (Treg) and effector T cells balance each
other to preserve homeostasis [31]. However, in diseases
with inflammatory signatures, the fragile balance between
protective function and immune modulation is dysregu-
lated. In particular, Treg cells play an important role in
immune tolerance and the resolution of inflammation. An
increase in inflammatory hyper-activation of effector
lymphocytes or impaired Treg functions represents com-
mon markers of chronic inflammation responsible for
immunological tissue injury [32]. Consequently, it is
important to consider the emergent functional properties
of the gut microbiome in relation to the modulation of
immune responses in relation to the gut-brain axis.
T lymphocytes play a crucial role in stroke progression. In
particular the pro-inflammatory lymphocytic gdT-IL-17+
cells have been shown to promote lesion development,Current Opinion in Neurobiology 2020, 61:1–9 whereas anti-inflammatory Treg cells are neuroprotective
[33,34]. A dysbiotic microbiome has been associated with
an increase of CD4+-IL-17 cells in the gut and IL-17
expression in the brain [12]. Additionally, colonization
of GF mice with a microbiome from a SPF mouse has been
found to be neuroprotective and showed a post-stroke
mounted T cell-helper response in the gut and in the brain.
These findings suggest that mice with a conventional
microbiome generate an adequate lymphocyte-driven
immune reaction in response to brain injury and trigger
tissue protection. Importantly, the microbiome-mediated
brain protection was absent in lymphocyte-deficient mice
[30]. Interestingly, it has been highlighted that environ-
mental factors modulating the gut microbiome are also
important in mounting an inflammatory response in the
gut. Indeed, mice from diverse commercial breeders
exhibit a substantial variation in their microbiota composi-
tion and this influences the intestinal T cell response and
the impact on stroke [16]. In another study, the key role of
immune cells educated by the gut microbiome has been
shown to have a considerable impact on stroke outcome
(Figure 2). Bacterial priming of dendritic cells results in an
expansion of Treg in the gut, which secrete IL-10 to
suppress pro-inflammatory IL-17+ gdT cells [11].
Although this modulation of immune cells by the micro-
biota occurs in the gut, its effects are relayed to the brain,
through T cell migration from the gut to the meninges
[11]. These findings highlight a direct connection along
the gut-brain axis via intestinal T cells regulating the
neuroinflammatory response to acute brain injury. In
contrast, the direct link of the gut microbiome as an
immunomodulator of AD and PD pathologies has not been
fully explored yet. However, there is clear evidence which
suggests that changes in the gut microbiome are associated
with peripheral immune response in addition to the central
neuroinflammation in AD and PD [29,35,36]. Under
physiological conditions the gut microbiome potently
communicates with the peripheral immune system.Hence,
gut microbiome shifts in AD patients can have a substantial
impact on amyloidogenesis and disease progression not
only by affecting cerebral immunity, but also by modulat-
ing the systemic immune response. In line with this
hypothesis, previous studies have demonstrated that
peripheral inflammation can modulate cerebral immunity
in AD and that brain-invading T cells from the blood
circulation also play a substantial role in AD-associated
neuroinflammation [37]. The role of inflammation in PD
[38] is reinforced by the observation that patients with
intestinal bowel disease taking anti-TNF-a therapy
and individuals being treated with non-steroidal anti-
inflammatory drugs are at a decreased risk for PD develop-
ment [39]. Colonic biopsies and fecal markers evidence an
elevated level of inflammatory cytokines in the gut and in
the blood [36,40]. In addition, migration of peripheral,
activated immunes cells to the brain has been described,
directly linking systemic andencephalic inflammation [41].
A recent study reinforced the notion that PD may be anwww.sciencedirect.com
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Microbiome-gut-brain axis in acute and chronic brain diseases.
Summary of the current knowledge on the biological mechanisms implicated in the bidirectional microbiome-gut-brain interactions in acute (stroke)
and chronic (AD and PD) brain disorders. Here is depicted the 3 main pathways of brain to gut communication: 1) immune cells via the blood
circulation, 2) vagus nerve axis and 3) hypothalamo-pituitary-adrenal axis (HPA). Highlighted in black are the pathways with evidence from animal
studies. In grey, are the un-investigated pathways. In particular, the role of the enteric nervous system and the possible bacteria-associated
mediators: hormones, metabolites, neurotransmitters, have not been discussed here.autoimmune disease, as approximately 40% of patients
have auto-reactive T-cells activated by SNCA peptides
[42]. Interestingly, both peripheral and neuroinflammation
as well as increased gut permeability are augmented in PD
[36]. Considering this complex interplay between periph-
eral immunity, the local immune response in the diseased
brain and the impact of inflammation on AD and PD
disease progression, it is conceivable that the microbiome
could have a substantial impact on this well-balanced
immunological network. Yet, the detailed mechanisms of
peripheral-central immune interactions and the immune-
active bacterial mediators involved herein are currentlywww.sciencedirect.com unexplored in chronic brain disorders and will require
numerous future studies.
Vagus nerve and the gut microbiome
The VN provides bi-directional neuronal ‘hardwiring’
and is a mediator of the gut microbiome’s effect in various
brain diseases. This nerve regulates gut motility, secre-
tions and inflammatory responses [43]. Studies in rodents
demonstrate that following lipopolysaccharide (LPS)
injection, the VN releases acetylcholine in the gut and
suppresses secretion of TNF-a by gut resident macro-
phages. Regulation of inflammation by the efferent VN isCurrent Opinion in Neurobiology 2020, 61:1–9
6 Neurobiology of diseaseboth local and systemic [44]. In PD patients, several
studies have investigated the impact of vagotomy, yet
due to the small number individuals, those studies have
so far failed to demonstrate a clear involvement [45].
Braak et al. proposed the ‘dual-hit hypothesis’, postulating
that a pathogen or a toxin may initiate PD pathogenesis
by promoting SNCA aggregation [46]. This hypothesis is
supported by animal studies where injection of fibrillar
SNCA into the induces SNCA spreading along the VN
toward the midbrain leading to neuronal damage [47,48].
Interestingly, SNCA aggregates are present in the
patient’s brain as well as along the gut-brain axis [49].
However, the role of the gut microbiome in affecting
SNCA aggregation and further regulating the transport of
SNCA to the CNS requires further study.
Despite these findings demonstrating a likely involve-
ment of the VN in acute [50] and chronic brain diseases
[51], its role in linking the gut microbiome to specific
disease progression has so far not been comprehensively
studied [45].
Microbial metabolites
Small molecules derived from the gut microbiome are the
molecular basis for host-microbiome crosstalk. Among
these molecules, a small fraction of bacterial metabolites
have been shown to impact the host neurophysiology via
multiple routes: blood circulation, humoral pathways, the
immune system or neuronal pathways [52].
Short chain fatty acids
The degradation of dietary fiber by gut microbiota pro-
duces large amounts of SCFAs: acetate, propionate and
butyrate in the gut. SCFAs enhance gut motility, lower
inflammatory cytokines and modulate the adaptive
immune tolerance as well as the level of gut hormones
and neuropeptides [53]. SCFAs have been directly impli-
cated in brain function, as for instance mono-colonization
by a butyrate-producing bacterium restores the GF
deficient BBB integrity and has a crucial role in the
maturation of microglia [8]. In a GF mouse model of
PD, the oral gavage with SCFAs promotes microglia
activation and motor dysfunction in comparison to GF
vehicle-treated mice [29]. Interestingly, the level of
SCFAs in human feces has been linked to PD pathology
[54]. Despite the key contribution of the gut microbiome
to stroke outcome as well as AD and the identification of
SCFAs as one of the microbiome’s main bioactive med-
iators, the role of SCFA and their potential therapeutic
use in stroke and AD has so far not been investigated
(Figure 1).
Tryptophan metabolites
Tryptophan is an essential amino acid — sourced by the
diet —, which is metabolized into the kynurenine path-
way by the host or into indoles by the gut microbiota.
Metabolites of tryptophan can modulate the intestinalCurrent Opinion in Neurobiology 2020, 61:1–9 immune cell function through the aryl hydrocarbon
receptor (AHR) [55]. Several studies have shown that
an increase in tryptophan catabolism is associated with
the severity of stroke outcome in patients and might be
related to the stroke-induced inflammatory response
[56,57]. Stanley and colleagues found that the predicted
metabolic KEGG pathway for xenobiotic biodegradation
was regulated in the intestinal mucosal microbiota in a
mouse model of stroke [15], suggesting that AHR ligands
are regulated after stroke. In PD patients, CSF levels of
tryptophan and kynurenic acid have been found to be
significantly lower compared to healthy controls [58].
However, more work is required to decipher how trypto-
phan metabolites derived from microbes are linked to
inflammation in brain disorders.
Membrane-derived molecules
Other gut microbiota-derived molecules have an important
impact on host immunity and neurological diseases. A
prominent example is the endotoxin lipopolysaccharide
(LPS) which is a marker for chronic inflammatory diseases.
Gut permeability facilitates LPS translocation and induces
a strong inflammatory response which can disrupt the BBB
and activate microglia [59]. In particular, gavage of
wild-type mice with Proteus mirabilis reproduces PD-like
symptoms and increased microglia activation via LPS [60].
Aggregation of amyloid proteins is a key molecular hall-
mark of AD and PD. Functional amyloids represent a
class of natively unfolded proteins produced by bacteria.
They are involved in the composition of bacterial biofilms
and are suggested to promote the aggregation of amyloid
proteins involved in neurodegenerative diseases [61]. In
the context of PD, one key study has revealed that gavage
of rats with the functional amyloid-Curli-producing
Escherichia coli, increases motors symptoms, SNCA aggre-
gation and neuronal loss [62]. This study was the
first showing a direct link between microbial amyloids,
SNCA aggregation and neurological symptoms. However,
further investigations are required to unravel the impact
of gut microbial amyloids on brain diseases.
Conclusions
Here, we have described the emerging roles for the gut
microbiome  in affecting the pathological outcomes of acute
and chronic brain disorders in animal models and human
studies (Figure 2). Whereas it is well established that the
microbiome  influences numerous metabolic and immuno-
logic aspects in health and disease, our understanding of how
exactly the microbiota modulates brain function before and
during disease progression is still limited. Studies implicat-
ing the microbiome-gut-brain axis have mainly involved
associations between gut microbiome composition and
disease symptomology.  Detailed investigations of the mech-
anistic components —immune, neuronal, metabolic — of
the complex bidirectional brain-gut interactions is requiredwww.sciencedirect.com
Gut-brain-axis in neurological diseases Benakis et al. 7to obtain a better understanding of the holistic aspects of
brain diseases.
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specific changes in the caecal microbiota of mice via
altered autonomic activity and mucoprotein production.
Brain Behav Immun 2016, 57:10-20.
15. Stanley D, Moore RJ, Wong CHY: An insight into intestinal
mucosal microbiota disruption after stroke. Sci Rep 2018,
8 568–12.
16. Sadler R, Singh V, Benakis C, Garzetti D, Brea D, Stecher B,
Anrather J, Liesz A: Microbiota differences between
commercial breeders impacts the post-stroke immune
response. Brain Behav Immun 2017, 66:23-30.
17. Spychala MS, Venna VR, Jandzinski M, Doran SJ, Durgan DJ,
Ganesh BP, Ajami NJ, Putluri N, Graf J, Bryan RM et al.: Age-
related changes in the gut microbiota influence systemic
inflammation and stroke outcome. Ann Neurol 2018, 84:23-36.
18. Yin J, Liao SX, He Y, Wang S, Xia GH, Liu FT, Zhu JJ, You C,
Chen Q, Zhou L et al.: Dysbiosis of gut microbiota with reduced
trimethylamine-N-oxide level in patients with large-artery
atherosclerotic stroke or transient ischemic attack. J Am Heart
Assoc 2015, 4:1-12.
19. Vogt NM, Kerby RL, Dill-McFarland KA, Harding SJ, Merluzzi AP,
Johnson SC, Carlsson CM, Asthana S, Zetterberg H, Blennow K
et al.: Gut microbiome alterations in Alzheimer’s disease. Sci
Rep 2017, 7:13537 http://dx.doi.org/10.1038/s41598-017-
13601-y.
20. Brandscheid C, Schuck F, Reinhardt S, Schäfer K-H, Pietrzik CU,
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Faßbender K, Schäfer K-H, Unger MM: Fecal markers of
intestinal inflammation and intestinal permeability areCurrent Opinion in Neurobiology 2020, 61:1–9 elevated in Parkinson’s disease. Parkinsonism Relat Disord
2018, 50:104-107.
37. Rakic S, Hung YMA, Smith M, So D, Tayler HM, Varney W, Wild J,
Harris S, Holmes C, Love S et al.: Systemic infection modifies
the neuroinflammatory response in late stage Alzheimer’s




Caggiu E, Arru G, Hosseini S, Niegowska M, Sechi G, Zarbo IR,
Sechi LA: Inflammation, infectious triggers, and Parkinson’s
disease. Front Neurol 2019, 10:122
This review paper gives a comprehensive view of the current literature
linking inflammation and PD.
39. Ascherio A, Schwarzschild MA: The epidemiology of
Parkinson’s disease: risk factors and prevention. Lancet Neurol
2016, 15(12):1257-1272 http://dx.doi.org/10.1016/S1474-4422
(16)30230-7.
40. Houser MC, Chang J, Factor SA, Molho ES, Zabetian CP,
Burns EMH, Payami H, Hertzberg VS, Tansey MG: Stool immune
profiles evince gastrointestinal inflammation in Parkinson’s
disease. Mov Disord 2018, 33:793-804.
41. Harms AS, Thome AD, Yan Z, Schonhoff AM, Williams GP, Li X,
Liu Y, Qin H, Benveniste EN, Standaert DG: Peripheral monocyte
entry is required for alpha-synuclein induced inflammation
and neurodegeneration in a model of Parkinson disease. Exp
Neurol 2017, 300:179-187.
42. Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J,
Liong C, McMurtrey C, Hildebrand WH, Mao X et al.: T cells from
patients with Parkinson’s disease recognize a-synuclein
peptides. Nature 2017, 546:656-661.
43. Bonaz B, Sinniger V, Pellissier S: Anti-inflammatory properties
of the vagus nerve: potential therapeutic implications of vagus
nerve stimulation. J Physiol 2016, 594:5781-5790.
44. Komegae EN, Farmer DGS, Brooks VL, McKinley MJ, McAllen RM,
Martelli D: Vagal afferent activation suppresses systemic
inflammation via the splanchnic anti-inflammatory pathway.
Brain Behav Immun 2018, 73:441-449 http://dx.doi.org/10.1016/j.
bbi.2018.06.005.
45. Breen DP, Halliday GM, Lang AE: Gut–brain axis and the spread
of a-synuclein pathology: vagal highway or dead end? Mov
Disord 2019, 34:307-316.
46. Rietdijk CD, Perez-Pardo P, Garssen J, van Wezel RJA,
Kraneveld AD: Exploring Braak’s hypothesis of Parkinson’s
disease. Front Neurol 2017, 8:473-479.
47. Kim S, Kwon S-H, Kam T-I, Panicker N, Karuppagounder SS, Lee S,
Lee JH, Kim WR, Kook M, Foss CA et al.: Transneuronal
propagation of pathologic a-synuclein from the gut to the brain
models Parkinson’s disease. Neuron 2019, 103:627-641.e7.
48. Van Den Berge N, Ferreira N, Gram H, Mikkelsen TW, Alstrup AKO,
Casadei N, Tsung-Pin P, Riess O, Nyengaard JR, Tamgüney G
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